

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/28, 33/24, 33/26</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/29115</b> <b>(43) International Publication Date:</b> 9 July 1998 (09.07.98)
<b>(21) International Application Number:</b> PCT/CA96/00875 <b>(22) International Filing Date:</b> 27 December 1996 (27.12.96) <b>(71) Applicant:</b> UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; 2194 Health Sciences Mall, IRC 331, Vancouver, British Columbia V6T 1Z3 (CA). <b>(72) Inventors:</b> LEGZDINS, Peter; 559 St. Giles Road, West Vancouver, British Columbia V7S 1L7 (CA). PANG, Catherine, C., Y.; 2971 West 30th Avenue, Vancouver, British Columbia V6L 1Z3 (CA). SHAW, Michael, J.; 102 Goyer Street, Cowansville, Quebec J2K 2C3 (CA). <b>(74) Agents:</b> NASSIF, Omar, A. et al.; Gowling, Strathy & Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> TRANSITION-METAL NITROSYL COMPOUNDS AS SMOOTH MUSCLE RELAXANTS  <b>(57) Abstract</b>  Compositions and methods for relaxing smooth muscle in a warm-blooded animal are provided, comprising the step of administering to the animal a transition-metal nitrosyl complex. In one aspect, the transition-metal nitrosyl complex is represented by the formula $L_3M(NO)_yX_{3-y}$ where L is a two-electron Lewis base or $L_3$ is a six-electron Lewis base, M is a Group 6 or 8 transition-metal, and when y is 1, X is carbon monoxide, and when y is 2, X is a halide or pseudohalide. In another aspect, the transition-metal nitrosyl complex is represented by the formula $[M(NO)_2X_y]_2$ where X is a halide or pseudohalide, and when M is a Group 6 transition-metal, y is 2, and when M is a Group 8 transition-metal, y is 1. Methods are also described for treating hypertension, angina pectoris, congestive heart disease, and impotence utilizing pharmaceutical compositions comprising the above-described transition-metal nitrosyl complexes.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Description

### TRANSITION-METAL NITROSYL COMPOUNDS AS SMOOTH MUSCLE RELAXANTS

#### 5 Technical Field

The present invention relates generally to compositions and methods of relaxing smooth muscles and, more specifically, to compositions and methods which utilize transition-metal nitrosyl compounds as smooth muscle relaxants.

#### 10 Background of the Invention

Muscle is divided into three types: skeletal, cardiac, and smooth. Briefly, smooth muscle is found in all muscles where contraction is involuntary, except for heart muscle. Generally, smooth muscle is composed of elongated, spindle-shaped, nucleated cells arranged parallel to one another and to the long axis of the muscle.

15 Smooth muscle is classified both functionally, and anatomically. When classified functionally, it is broken into two groups: multi-unit, and single-unit smooth muscle. Briefly, multi-unit smooth muscle is activated by nerves which cause contraction of independent muscle units, and thus is not spontaneously active. Examples of multi-unit muscle may be found in large arteries and veins, the urinary bladder, and  
20 the iris and ciliary muscles of the eye. In contrast to multi-unit smooth muscle, single-unit smooth muscle is usually spontaneously active, and contains tight junctions which facilitate the contraction of the muscle as a single unit. Examples of single-unit smooth muscle may be found in the vasculature (small veins, small arteries, and arterioles), the bile duct, and the walls of the gastrointestinal and urinogenital systems (gut, ureter, and  
25 uterus).

When smooth muscle is anatomically classified, it is generally divided into two groups: vascular and non-vascular. Briefly, vascular smooth muscle consists only of blood vessels (arteries, arterioles, and veins), whereas non-vascular muscle includes all other types of smooth muscle (*e.g.*, gastrointestinal (stomach, duodenum, ileum, jejunum, caecum, and colon), spleen, trachea/bronchus, seminal vesicle, ductus deferens, corpus cavernosum, biliary tract, ureter, and uterus).

Many diseases are characterized by the inability of smooth muscle to relax. For example, hypertension is a disease found in 15%-20% of all adults in the United States. This condition is characterized by persistently high arterial blood  
35 pressure which, if left untreated, may lead to other serious cardiovascular diseases such as heart failure, ischemia, renal failure, and stroke. Hypertension is one of the most important public health problems facing developed countries.

Because of the health risk associated with untreated hypertension, the importance of treating those who suffer from elevated blood pressure has been recognized. Clinical trials have shown that appropriate pharmacological treatment of patients with moderate or severe hypertension reduces the risk of stroke, renal failure, and congestive heart failure. Based upon these studies, patients are now commonly treated with antihypertensive drugs in order to lower diastolic blood pressure ("DBP") to levels below 90 mmHg. Common drugs which are used for this purpose include diuretics (hydrochlorothiazide, chlorthalidone), sympatholytics (clonidine, atenolol, prazosin), vasodilators (minoxidil, sodium nitroprusside), angiotensin converting enzyme inhibitors (captopril, enalapril), and calcium entry blockers (nifedipine, nitrendipine). The selection of a specific drug depends upon the severity of the disease, the patient's age and lifestyle, side effects, cost, and concomitant diseases and therapies.

One approach to the treatment of hypertension is to effect the reduction of elevated blood pressure through blood vessel dilation, which results in an increase of blood vessel diameter and concomitant blood pressure reduction. One class of compounds which are commonly utilized to dilate blood vessels are nitrovasodilators, which have been utilized for the relief of anginal attacks and the treatment of hypertension. Clinically useful nitrovasodilators include organic nitrites and nitrates such as amyl nitrite, glyceryl trinitrate (nitroglycerin), isosorbide dinitrate, erythrityl tetranitrate, and pentaerythritol as well as an inorganic nitric oxide donor, sodium nitroprusside.

Nitroglycerin and sodium nitroprusside are the most commonly used nitrovasodilators. Nitroglycerin is therapeutically useful for the treatment of angina pectoris and gastrointestinal spasm, while sodium nitroprusside is primarily utilized for the treatment of hypertensive emergencies. Nitroglycerin may either be administered at the time of anginal attack or prophylactically in anticipation of exercise or stress. Although nitroglycerin is effective in relief of acute attack, continual exposure to nitroglycerin and other organic nitrates results in a reduction in the ability of these compounds to vasodilate blood vessels. Because of the tolerance that develops from their chronic use, these nitrovasodilators have limited applicability.

Sodium nitroprusside is likewise effective in lowering blood pressure, although its use is primarily limited to hypertensive emergencies due to its efficacy and toxicity. In particular, the infusion of sodium nitroprusside at high doses or for long periods of time (over 24 hours) is associated with the toxicities resulting from the accumulation of cyanide and or thiocyanate.

Accordingly, there is a need in the art for physiologically acceptable smooth muscle relaxants which do not result in the development of tolerance and do not

have toxic side effects. The present invention fulfills these needs, and further, provides other, related advantages.

#### Summary of the Invention

5 Briefly stated, the present invention provides methods for relaxing smooth muscle in a warm-blooded animal, comprising the step of administering to the animal a therapeutically effective amount of a transition-metal nitrosyl complex. Within one aspect of the invention, the transition-metal nitrosyl complex is represented by the formula  $L_3M(NO)_yX_{3-y}$  where L is a two-electron Lewis base or  $L_3$  is a six-electron  
10 Lewis base, M is a Group 6 or 8 transition-metal, and when y is 2, X is either a halide or pseudohalide, and when y is 1,  $X_2$  is either  $L_2$  or XL.

Within another aspect of the invention, methods are provided for relaxing smooth muscle in a warm-blooded animal, comprising administering to the animal a transition-metal nitrosyl complex represented by the formula  $[M(NO)_2X_y]_2$  where M is a  
15 Group 6 or 8 transition-metal, X is either a halide or pseudohalide, and when M is a Group 6 transition-metal, y is 2, and when M is a Group 8 transition-metal, y is 1.

A further aspect of the present invention provide methods for treating hypertension in a warm-blooded animal, comprising administering to the animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by  
20 either the formula  $L_3M(NO)_yX_{3-y}$  or  $[M(NO)_2X_y]_2$  as described above.

Within another aspect of the present invention, methods for treating angina pectoris in a warm-blooded animal are provided, comprising administering to the animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by either the formula  $L_3M(NO)_yX_{3-y}$  or  $[M(NO)_2X_y]_2$  as described above is  
25 disclosed.

A further aspect of the present invention provides methods for treating congestive heart failure in a warm-blooded animal, comprising administering to the animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by either the formula  $L_3M(NO)_yX_{3-y}$  or  $[M(NO)_2X_y]_2$  as described above.

30 Within a further aspect of the present invention, methods for treating impotence in a warm-blooded animal are provided, comprising administering to the animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by either the formula  $L_3M(NO)_yX_{3-y}$  or  $[M(NO)_2X_y]_2$  as described above is disclosed.

35 Another aspect of the present invention provides pharmaceutical compositions comprising a transition-metal nitrosyl complex and a pharmaceutically acceptable carrier or diluent. The transition-metal nitrosyl complex of the

pharmaceutical composition may be represented by either the formula  $L_3M(NO)_yX_{3-y}$  or  $[M(NO)_2X_y]_2$  as described above. These pharmaceutical compositions may be utilized in the methods described above, as well as in a variety of *in vitro* and *in vivo* assays which are discussed in more detail below and in the Examples.

5                These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings.

#### Brief Description of Drawings

10                Figure 1 is a graph which illustrates the effects of  $CpCr(NO)_2Cl$  and  $CpMo(NO)_2Cl$  on the relaxation of phenylephrine-precontracted rat aortic rings (1A) and the change in mean arterial blood pressure in conscious rats (1B).

15                Figure 2 is a graph which illustrates the effects of pre-incubation with vehicle,  $CpCr(NO)_2Cl$ , and nitroglycerin on subsequent relaxation responses to  $CpCr(NO)_2Cl$ , nitroglycerin, and sodium nitroprusside of phenylephrine-precontracted rat aortic rings.

#### Detailed Description of the Invention

20                As noted above, the present invention is directed toward transition-metal nitrosyl complexes which are effective in relaxing smooth muscle *in vivo*, without the development of tolerance associated with organic nitrites and nitrates such as nitroglycerin, and without the toxic side effects of sodium nitroprusside. As smooth muscle relaxants, these transition-metal nitrosyl complexes are useful as pharmaceutical compositions for the treatment of a variety of conditions wherein it is desired to relax smooth muscles, including for example, hypertension, angina pectoris, congestive heart failure, and impotence, as well as a variety of *in vitro* and *in vivo* assays described below.

30                The transition-metal nitrosyl complexes of the present invention may be generally represented by the formula  $L_3M(NO)_yX_{3-y}$  wherein L is a two-electron Lewis base or  $L_3$  is a six-electron Lewis base, wherein M is a transition-metal, wherein X is a halide or a pseudohalide, and wherein if y is 1, X is carbon monoxide and if y is 2, X is a halide or pseudohalide. As used herein, the term "transition-metal nitrosyl complex" refers to a composition in which a transition-metal is coordinatively complexed with ligands wherein at least one ligand is nitric oxide. The term "nitrosyl" refers to the nitric oxide ligand. A transition-metal is defined as any metal that is a member of Periodic Groups 3-12. Preferred transition-metals include Groups 6 and 8 metals; chromium, molybdenum, tungsten, and iron, ruthenium, osmium, respectively. A more preferred embodiment of the present invention comprises transition-metals from Group 6. As

35

represented by the formula  $L_3M(NO)_yX_{3-y}$ , the transition-metal ligands are L, NO (nitric oxide), and X wherein L is a two-electron Lewis base or  $L_3$  is a six-electron Lewis base and X is a halide or a pseudohalide, or alternatively, a two-electron Lewis base, L. As used herein, the term "Lewis base" refers to any chemical species which is an electron pair donor. Two-electron Lewis bases are those bases which may donate a single pair of electrons. Suitable two-electron Lewis bases include bases which bear atoms from Periodic Groups 15 and 16. Lewis bases from Group 15 contain nitrogen, phosphorous, arsenic, antimony or bismuth atoms as electron pair donors. Preferable Lewis bases from Group 15 contain nitrogen, phosphorous, and antimony, and more preferably, nitrogen or phosphorous. Nitrogen containing Lewis bases include ammonia and its carbon substituted derivatives including primary, secondary, and tertiary amines and aromatic amines including pyridine and pyrrole as well as saturated analogs, piperidine and pyrrolidine. Other preferable nitrogen containing Lewis bases include amino acids and their derivatives. Phosphorous containing Lewis bases include phosphine and its carbon substituted derivatives including primary, secondary, and tertiary phosphines as well as alkoxy substituted derivatives including primary, secondary, and tertiary phosphites. Lewis bases from Group 16 contain oxygen, sulfur, or selenium atoms as electron pair donors. Preferable Lewis bases from Group 16 contain oxygen or sulfur. Oxygen containing Lewis bases include water and alcohols and sulfur containing bases include hydrogen sulfide and thiols. Carbon monoxide is also a two-electron Lewis base. The transition-metal nitrosyl complex may also have a six-electron Lewis base as ligand. As represented by  $L_3M(NO)_yX_{3-y}$ ,  $L_3$  may represent a six-electron Lewis base. Six-electron Lewis bases include bases such as cyclopentadienyl anion and derivatives. In a preferred embodiment, the six-electron Lewis base is permethylcyclopentadienyl anion, and in a most preferred embodiment, the six-electron Lewis base is cyclopentadienyl anion. The transition-metal nitrosyl complex may also bear ligand X wherein X may be carbon monoxide where y is 1, and wherein X may be either a halide or pseudohalide where y is 2. Suitable halides include fluoride, chloride, bromide, and iodide. Preferred halides include chloride and iodide. Suitable pseudohalides include nitrite, nitrate, and cyanide anion.

In a preferred embodiment of the invention, the transition-metal nitrosyl complex may bear two nitrosyl ligands. In particular, the transition-metal nitrosyl complex represented by the general formula  $L_3M(NO)_yX_{3-y}$  where y is 2 becomes  $L_3M(NO)_2X$ . In a most preferred embodiment, the six-electron Lewis base,  $L_3$ , is cyclopentadienyl anion; X may be selected from the group consisting of chloride and nitro; and the transition-metal, M, may be selected from the group consisting of chromium, molybdenum, and tungsten.

In another preferred embodiment, the transition-metal may bear a single nitrosyl ligand. The transition-metal nitrosyl complex represented by the general formula  $L_3M(NO)_yX_{3-y}$  where  $y$  is 1 becomes  $L_3M(NO)X_2$ . In a most preferred embodiment, the six-electron Lewis base,  $L_3$ , is cyclopentadienyl anion;  $X$  is carbon monoxide; and the transition-metal,  $M$ , may be selected from the group consisting of chromium, molybdenum, and tungsten.

In yet another embodiment, the transition-metal nitrosyl complex bears a single nitrosyl ligand and is represented by the formula  $L_3M(NO)X_2$  where  $X_2$  may be  $XL$ . Such a transition-metal nitrosyl complex is represented by the formula  $L_3M(NO)XL$ . In a most preferred embodiment the six-electron Lewis base,  $L_3$ , is cyclopentadienyl anion;  $X$  is iodide; the two-electron Lewis base,  $L$ , may be selected from the group consisting of pyridine, piperidine, and trimethylphosphite; and the transition-metal,  $M$ , may be selected from the group consisting of chromium, molybdenum, and tungsten.

Within another aspect of the present invention, transition-metal nitrosyl complexes of the present invention may be represented by the formula  $[M(NO)_2X_y]_2$  wherein  $M$  is a Group 6 or 8 transition metal,  $X$  is a halide or pseudohalide, and when  $M$  is a Group 6 transition-metal,  $y$  is 2, and when  $M$  is a Group 8 transition-metal,  $y$  is 1.

Some of the transition-metal nitrosyl complexes of the present invention are soluble in water and may be formulated as solutions in normal saline (0.9% sodium chloride). Water-insoluble complexes or complexes which have difficulty dissolving in water may be dissolved in 100% dimethylsulfoxide (DMSO), 60% DMSO in water, or 1:1 DMSO:Tween 80 followed by dilution with normal saline. Some complexes may require 10-20 minutes sonication to effect solution.

The transition-metal nitrosyl complexes of the present invention may be formulated as pharmaceutical compositions suitable for administration to a warm-blooded animal. Such formulations may contain an effective amount of the transition-metal nitrosyl complex as well as one or more pharmaceutically acceptable carriers and diluents. More specifically, the pharmaceutical compositions of the present invention may be administered as liquids, emulsions, or suspensions containing acceptable diluents such as alcohols and sterile water containing sugars, salts, preservatives, suspending agents, emulsifying agents, or administered as lotions, creams, or gels containing acceptable diluents, preservatives, or carriers to impart the desired texture, consistency, and viscosity. Such acceptable diluents and carriers are familiar to those skilled in the art, and include (but are not limited to) emulsifying agents such as non-ionic ethoxylated and non-ethoxylated surfactants, fatty alcohols, fatty acids, preserving agents, wax esters, triglyceride esters, steroid alcohols, phospholipids such as lecithin and cephalin,



polyhydric alcohol esters, fatty acid esters, hydrophilic lanolin derivatives, hydrophobic beeswax derivatives, hydrocarbon oils (such as palm oil, coconut oil, and mineral oil), cocoa butter waxes, silicon oils, pH balancers, and cellulose derivatives. The present invention may be administered as tablets or capsules which may contain suitable diluents,  
5 or administered as inhalations, sprays or aerosols which may contain propellant, or aqueous or oily vehicles, or administered as suppositories which may contain cocoa butter, glycerinated gelatin or other suitable bases.

Preferably, pharmaceutical compositions of the present invention are formulated for the particular method of administration (*e.g.*, intravenous, topical,  
10 pulmonary, rectal, sublingual, intramuscular, or oral), and in a manner which is in accordance with accepted practices, such as disclosed in *Remington's Pharmaceutical Sciences*, Gennaro, Ed., Mack Publishing Co., Easton, PA 1990 (which is incorporated herein by reference in its entirety). In addition, pharmaceutical compositions of the present invention may be placed within containers, along with packaging material which  
15 indicates that the pharmaceutical composition may be utilized to relax smooth muscles.

As noted above, the present invention also provides methods for relaxing smooth muscle in a warm-blooded animal (*e.g.*, humans, chimps, cows, goats, pigs, dogs, cats, rats or mice) comprising the step of administering to the animal a therapeutically effective amount of a transition-metal nitrosyl complex as described  
20 above. Briefly, the efficacy (and therapeutically effective amount) of a particular transition-metal nitrosyl complex may be readily determined by both *in vitro* and *in vivo* techniques. See generally Blattner et al., *Experiments on Isolated Smooth Muscle Preparations*, Hugo Sachs Elektronik KG, 1980 (incorporated herein by reference in its entirety). For example, within one embodiment, a small animal such as a rat, rabbit, or  
25 guinea-pig is sacrificed and exsanguinated. The required tissue (*e.g.*, artery, vein, stomach, ileum, jejunum, caecum, colon, uterus, spleen, trachea, seminal vesicle, ductus deferens, or corpus cavernosum) is removed and placed in an oxygenated physiological solution (*e.g.*, Krebs or Tyrode solution). This tissue is then cut such that one end is attached to the bottom of a muscle bath, and the other end to a force-displacement  
30 transducer (for example, Grass FT-03-C, Quincy, MA) for isometric recording with a physiological recorder (Grass, Model 79G). An appropriate pre-load (0.5 to 10 grams, depending on the tissue) is then applied, and the tissue equilibrated in the bath for one hour prior to the start of the study.

The measurement of smooth muscle contractile response may then be  
35 performed essentially as described by Pang and Sutter in *Blood Vessels* 17:293-301, 1980 (incorporated herein by reference in its entirety). Briefly, a dose-response curve of an agonist (*e.g.*, phenylephrine, norepinephrine) is first obtained by measuring

contractile response of the muscle as a function of agonist concentration. Response to the agonist is then measured beginning with the addition of the lowest dose of agonist to the bath. Each dose is equilibrated in the bath for 2 to 6 minutes in order to assure a steady state response, prior to proceeding to the next higher dose.

5                    Measurement of the effectiveness of smooth muscle relaxant compositions may then be determined by measurement of the smooth muscle relaxation response, in a manner analogous to contractile response. *See generally* Wang, Poon and Pang, *J. Pharm. Exp. Ther.* 265:112-119, 1993 (incorporated herein by reference in its entirety). Briefly, tissue is first contracted with an agonist such as phenylephrine, usually  
10                    at a concentration which results in 90% of the tissue's maximum contractile response (referred to EC<sub>90</sub>). At the steady state phase of the contractile response to the agonist, a cumulative dose-response curve for the smooth muscle relaxant may be determined. For each concentration of relaxant, a steady state is achieved and the relaxation response measured. The effective concentration (EC) of a relaxant is the concentration that  
15                    produces relaxation of a contraction previously induced by an agonist. For example, the EC<sub>50</sub> of a relaxant is the effective concentration of the relaxant required to relax a pre-contracted muscle to 50% of its maximum contractile response.

                    As described in more detail below, transition-metal nitrosyl complexes of the present invention have been demonstrated to be effective in the relaxation of smooth  
20                    muscle *in vitro*. In particular, a series of transition-metal nitrosyl complexes were tested for their ability to relax pre-constricted rat aortic rings *in vitro*. All of the transition-metal nitrosyl complexes completely and dose-dependently relaxed phenylephrine pre-constricted aortae with efficacies similar to that of sodium nitroprusside. The results of the *in vitro* relaxation experiments are presented in Example 5 and Table 1. (See  
25                    Example 5 for experimental detail.)

                    Likewise, *in vivo* tests may also be readily developed and utilized in order to determine the efficacy (and therapeutically effective amount) of the transition-metal nitrosyl complexes described above. For example, within one aspect of the present invention, a series of transition-metal nitrosyl complexes were tested *in vivo* for their  
30                    ability to reduce the mean arterial blood pressure of conscious rats *in vivo*. Briefly, as described in greater detail below in Example 6, conscious, unrestrained rats were intravenous bolus injected with the transition-metal nitrosyl complexes. Five of the complexes were determined to dose-dependently reduce mean arterial pressure with maximum depressor effects which ranged from -36 to -59 mm Hg. Maximum depressor  
35                    effects of sodium nitroprusside and nitroglycerin under similar conditions were -58 and -56 mm Hg, respectively. Three of the complexes exhibited potencies similar to, or greater than, that of nitroglycerin, and two of the complexes were found to be more

potent than sodium nitroprusside. The results of the effects of the transition-metal nitrosyl complexes on the depression of mean arterial pressure in conscious rats *in vivo* are summarized in Example 5 and Table 1.

In addition to determining efficacy of transition-metal nitrosyl complexes in either *in vitro* or *in vivo* tests, it is also generally preferable to determine whether the composition induces tolerance. For example, within one embodiment of the invention, induction of tolerance by the transition-metal nitrosyl complex described above may be readily determined by exposing rat aortic rings to a transition-metal nitrosyl complex prior to relaxation determinations. More specifically, as described in greater detail below in Example 7, intact rat aortic rings were pre-incubated with a typical transition-metal nitrosyl complex for one hour prior to examination of its concentration-relaxation effect in phenylephrine-precontracted conditions. Unlike the relaxation response of nitroglycerin, the relaxation response of the transition-metal nitrosyl complexes was not diminished by pre-exposure of the aortic ring to the complex. The results indicate that tolerance develops less rapidly with the transition-metal nitrosyl complexes of the present invention than with nitroglycerin.

As noted above, transition-metal nitrosyl complexes of the present invention may be readily administered to a warm-blooded animal in order to relax a variety of smooth muscles. For example, within one aspect of the present invention, therapeutically effective amounts of a transition-metal nitrosyl complex may be administered to a warm-blooded animal in order to relax vascular smooth muscles. Through such methods, transition-metal nitrosyl complexes may be utilized in order to treat a variety of vascular disorders, including for example, hypertension, angina pectoris, and congestive heart failure.

The present invention also provides methods for relaxing nonvascular smooth muscle through the administration of the transition-metal nitrosyl complexes described above. For example, within one aspect of the present invention methods are provided for treating impotence, comprising the step of administering to a warm-blooded animal a transition-metal nitrosyl complex as described above. The effectiveness of the transition-metal nitrosyl complexes described above for the treatment of impotence may readily be evaluated through both *in vitro* and *in vivo* investigation. More specifically, *in vitro* evaluation may be accomplished utilizing corpus cavernosum excised from the penis of a rabbit, which is then dissected free from the tunica albuginea, cut into strips and mounted at resting tension. Phenylephrine-precontracted strips may be used in procedures similar to those described above, and in the examples, in order to construct dose-response curves for the transition-metal nitrosyl complexes.

Similarly, *in vivo* studies may likewise be utilized in order to test the efficacy of the transition-metal nitrosyl complexes described above in the treatment of impotence. Briefly, previous *in vivo* studies involving the systemic or central administration of low doses of apomorphine and other dopaminergic agonists, have  
5 shown that penile erection and yawning can be reliably induced in rats (Heaton et al., *J. Urol.* 145:1099-102, 1991). Therefore, *in vivo* studies may be utilized in order to investigate the utility of the transition-metal nitrosyl complexes of the present invention to facilitate apomorphine-induced penile erection in rats. For example, within one embodiment of the invention rats are individually placed in Plexiglas cages which have a  
10 mirror arranged in an oblique position to enhance observation. Pretreatment of the rats with a transition-metal nitrosyl complex may then be utilized to generate dose-response curves for apomorphine-induced rat penile erections.

Within another aspect of the present invention, methods are provided for enhancing learning and memory in warm-blooded animals, comprising the step of  
15 administering to a warm-blooded animal one of the above-described transition-metal nitrosyl complexes. The efficacy of such complexes in enhancing memory and learning may be readily ascertained through a variety of tests, including, for example, the Morris water maze performance test for rats. See Morris, *Learn Motiv.* 12:239-60, 1981; Decker and Majchrzak, *Psychopharmacol.* 107:530-34, 1992. Briefly, rats are given  
20 daily injections of various doses of transition-metal nitrosyl complexes at a time just prior to swimming sessions. The rats are then trained several times daily over a period of several days in a pool filled with warm milk. In each training trial, the rats are given a short period to find a submerged escape platform placed in one of the quadrants of the pool. Those not locating the platform will be guided to it. The mean escape latency on  
25 each training day may be determined as an index of information acquisition. The amount of time the rat spends in the training quadrant where the escape platform had been located during training will be indicative of acquired spatial information. The effect of transition-metal nitrosyl complexes on acquired spatial information may reflect the utility of these complexes in learning and memory.

30 Transition-metal nitrosyl complexes of the present invention have demonstrated beneficial vasodilation properties through their capacity to relax blood vessels *in vitro* and depress blood pressure *in vivo*. Furthermore, the complexes are as effective in vasodilation as existing nitrovasodilators, nitroglycerin and sodium nitroprusside. Additionally, the complexes do not appear to cause the adverse effect of  
35 tolerance associated with nitroglycerin nor toxicity associated with either nitroglycerin or sodium nitroprusside.

The following examples are offered by way of illustration, and not by way of limitation.

## EXAMPLES

Examples 1-4 describe the preparation of the transition-metal nitrosyl complexes. All manipulations of compounds described in Examples 1-4 were performed under an atmosphere of prepurified dinitrogen or argon. All solvents were distilled from appropriate drying agents and degassed prior to use. Standard Schlenk and glove-box techniques were used throughout. Unless otherwise indicated, all other reactions and manipulations were carried out in a well ventilated fume hood. In these examples, the following abbreviations are used: THF, tetrahydrofuran; CH<sub>2</sub>Cl<sub>2</sub>, dichloromethane; IR, infrared spectrum;  $\nu$  refers to frequency; EIMS, electron impact mass spectroscopy; P<sup>+</sup> refers to parent ion; <sup>1</sup>H NMR, proton nuclear magnetic resonance; CDCl<sub>3</sub>, deuteriochloroform; mp, melting point; FAB, fast atom bombardment; P(OMe)<sub>3</sub>, trimethylphosphite; C<sub>5</sub>H<sub>11</sub>N, pip, piperidine; C<sub>5</sub>H<sub>5</sub>N, py, pyridine.

Examples 5-7 present *in vitro* and *in vivo* results of the evaluation of the efficiency of the transition-metal nitrosyl complexes in relaxing blood vessels and lowering blood pressure. Sprague-Dawley rats (300-400g) were used for all experiments. Each group consisted of 1-6 rats for the *in vivo* experiments and 3-6 aortic rings for the *in vitro* experiments. Each aortic ring was from a different rat.

EXAMPLE 1The Synthesis of Transition-Metal Nitrosyl Complexes  
with Formula L<sub>3</sub>M(NO)X<sub>2</sub>

Example 1 presents the syntheses of the transition-metal nitrosyl complexes generally represented by the formula L<sub>3</sub>M(NO)<sub>y</sub>X<sub>3-y</sub> where y is 1: L<sub>3</sub>M(NO)X<sub>2</sub>.

A. Preparation of Dicarbonyl( $\eta^5$ -cyclopentadienyl) nitrosyl Complexes of  
Chromium, Molybdenum, and Tungsten

Briefly, a 200-mL, three-necked flask is fitted with a nitrogen inlet and stirrer and is thoroughly flushed with prepurified dinitrogen. A dry THF solution (50 mL) containing 4.18 g of sodium cyclopentadienide, Na[C<sub>5</sub>H<sub>5</sub>] is syringed into the flask, and Cr(CO)<sub>6</sub> (11.00 g, 50.0 mmol) and 100 mL of di-*n*-butyl ether are added. (In the case of molybdenum and tungsten the di-*n*-butyl ether is not added.) The flask is then equipped with a Leibig condenser and the reaction mixture is refluxed with vigorous

stirring for 12 h. During this time, the reaction vessel is shaken occasionally to reintroduce any sublimed  $\text{Cr}(\text{CO})_6$  into the refluxing reaction mixture. The final reaction mixture is allowed to cool to room temperature and filtered, and the pale-yellow solid thus collected is washed with diethyl ether (3 x 10 mL), and dried under nitrogen. The excess  $\text{Cr}(\text{CO})_6$  and any di-*n*-butyl ether remaining in this solid are removed by sublimation at 90°C/0.005 torr onto a water-cooled probe. The  $\text{Na}[(\eta^5\text{-C}_5\text{H}_5)\text{M}(\text{CO})_3]$  complexes of molybdenum and tungsten are freed of any unreacted hexacarbonyl in a similar fashion, and all three sodium salts are used without further purification.

The preparations of all three  $(\eta^5\text{-C}_5\text{H}_5)\text{M}(\text{CO})_2(\text{NO})$  complexes from their corresponding  $[(\eta^5\text{-C}_5\text{H}_5)\text{M}(\text{CO})_3]^-$  anions are similar. The experimental procedure using the tungsten complex dicarbonyl( $\eta^5$ -cyclopentadienyl)nitrosyltungsten, is given below.

A 300-mL, three-necked flask is equipped with a nitrogen inlet, an addition funnel, and a stirrer. It is charged with  $\text{Na}[(\eta^5\text{-C}_5\text{H}_5)\text{W}(\text{CO})_3]$  (17.3 g, 48.5 mmol) and THF (120 mL). A THF solution (50 mL) containing Diazald (N-methyl-N-nitroso-p-toluenesulfonamide, Aldrich Chemical Co.) (10.4 g, 48.6 mmol) is syringed into the addition funnel. The solution of Diazald is added dropwise over a period of 15 minutes and the solvent is removed *in vacuo*. Sublimation of the resulting brown residue at 50-60°C/0.005 torr onto a water-cooled probe for three days affords  $(\eta^5\text{-C}_5\text{H}_5)\text{W}(\text{CO})_2(\text{NO})$  (13.6 g, 84% yield).

The corresponding chromium and molybdenum complexes are obtained similarly in yields of 60 and 93% respectively. The compounds are orange to orange-red solids readily soluble in organic solvents. The solids are stable in air for short periods of time and indefinitely under dinitrogen.

Analysis calculated for  $\text{C}_5\text{H}_5\text{Cr}(\text{CO})_2(\text{NO})$ : C, 41.39; H, 2.48; N, 6.90. Found: C, 41.40; H, 2.60; N, 6.70. IR ( $\text{CH}_2\text{Cl}_2$ ):  $\nu_{\text{CO}}$  2020, 1945;  $\nu_{\text{NO}}$  1680  $\text{cm}^{-1}$ . EIMS (probe temperature 120°C):  $m/z$  203 [ $\text{P}^+$ ].

Analysis calculated for  $\text{C}_5\text{H}_5\text{Mo}(\text{CO})_2(\text{NO})$ : C, 34.03; H, 2.04; N, 5.67. Found: C, 34.28; H, 2.24; N, 5.54. IR ( $\text{CH}_2\text{Cl}_2$ ):  $\nu_{\text{CO}}$  2020, 1937;  $\nu_{\text{NO}}$  1663  $\text{cm}^{-1}$ . EIMS (probe temperature 120°C):  $m/z$  249 [ $\text{P}^+$ ].

Analysis calculated for  $\text{C}_5\text{H}_5\text{W}(\text{CO})_2(\text{NO})$ : C, 25.10; H, 1.50; N, 4.18. Found: C, 25.29; H, 1.70; N, 4.13. IR ( $\text{CH}_2\text{Cl}_2$ ):  $\nu_{\text{CO}}$  2010, 1925;  $\nu_{\text{NO}}$  1655  $\text{cm}^{-1}$ . EIMS (probe temperature 120°C):  $m/z$  319 [ $\text{P}^+$ ].

B. Preparation of Dicarbonyl( $\eta^5$ -permethylcyclopentadienyl)nitrosyl Complexes of Molybdenum and Tungsten

The permethylated complexes,  $(\eta^5\text{-C}_5\text{Me}_5)\text{M}(\text{CO})_2(\text{NO})$  ( $\text{M} = \text{Mo}, \text{W}$ ) are prepared in a manner similar to that of their cyclopentadienyl analogues except that  $\text{Li}[\text{C}_5\text{Me}_5]$  is used instead of  $\text{Na}[\text{C}_5\text{H}_5]$ , and that higher temperatures ( $100^\circ\text{C}$ ) are required to effect their sublimation.

5            Analysis calculated for  $\text{C}_{10}\text{H}_{15}\text{Mo}(\text{CO})_2(\text{NO})$ : C, 36.17; H, 4.55; N, 4.22. Found: C, 36.17; H, 4.60; N, 4.30. IR ( $\text{CH}_2\text{Cl}_2$ ):  $\nu_{\text{NO}}$  1659  $\text{cm}^{-1}$ . EIMS (probe temperature  $120^\circ\text{C}$ ):  $m/z$  333  $[\text{P}^+]$ .  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$  1.95 (s).

             Analysis calculated for  $\text{C}_{10}\text{H}_{15}\text{W}(\text{CO})_2(\text{NO})$ : C, 22.93; H, 1.92; N, 5.34. Found: C, 22.96; H, 1.87; N, 5.26. IR ( $\text{CH}_2\text{Cl}_2$ ):  $\nu_{\text{NO}}$  1690  $\text{cm}^{-1}$ . EIMS (probe  
10    temperature  $120^\circ\text{C}$ ):  $m/z$  421  $[\text{P}^+]$ .

## EXAMPLE 2

### The Synthesis of Transition-Metal Nitrosyl Complexes 15            with Formula $\text{L}_3\text{M}(\text{NO})_2\text{X}$

This example presents the synthesis of the transition-metal nitrosyl complexes generally represented by the formula  $\text{L}_3\text{M}(\text{NO})_y\text{X}_{3-y}$  where y is 2:  $\text{L}_3\text{M}(\text{NO})_2\text{X}$ .

20

#### A.    Preparation of Chloro( $\eta^5$ -cyclopentadienyl)dinitrosyl Complexes of Chromium, Molybdenum, and Tungsten

Approximately 2-3 mL of nitrosyl chloride is condensed into a 5-mL graduated cold trap held at  $-78^\circ\text{C}$ . It is then allowed to melt so that its volume can be  
25    measured, and it is distilled under static vacuum into a 100-mL, two-necked flask held at  $-78^\circ\text{C}$  until just prior to use when it is allowed to warm to room temperature.

All three  $(\eta^5\text{-C}_5\text{H}_5)\text{M}(\text{NO})_2\text{Cl}$  complexes are prepared in a similar manner, but to achieve maximum yields of the chromium and molybdenum compounds, the reactions should be performed at  $-78^\circ\text{C}$ . The molybdenum complex (chloro( $\eta^5$ -  
30    cyclopentadienyl)nitrosylmolybdenum), on the other hand, can be obtained in excellent yields even at room temperature as disclosed below.

A 200-mL, three-necked flask, equipped with a stirrer, a nitrogen inlet, and an addition funnel, is charged with  $(\eta^5\text{-C}_5\text{H}_5)\text{Mo}(\text{CO})_2(\text{NO})$  (6.5 g, 26 mmol) and  $\text{CH}_2\text{Cl}_2$  (100 mL). The nitrosyl chloride solution (typically containing 2.3 mL (50  
35    mmol) of nitrosyl chloride in 30 mL of  $\text{CH}_2\text{Cl}_2$ ) is added dropwise to the stirred reaction mixture. Gas evolution occurs and the orange solution becomes dark green. The reaction is monitored by infrared spectroscopy and the nitrosyl chloride solution is



added until the carbonyl absorptions of the initial organometallic reactant have disappeared. It is extremely important that a stoichiometric amount of nitrosyl chloride (ClNO) be used, since even a slight excess of ClNO reduces significantly the yields of the desired products, especially in the cases of the chromium and tungsten complexes.

- 5 Conversely, if an insufficient quantity of ClNO is added, the separation of any unreacted ( $\eta^5\text{-C}_5\text{H}_5$ )M(CO)<sub>2</sub>(NO) from the desired chloronitrosyl complex is difficult. The final reaction mixture is concentrated in vacuo to approximately 30 mL, and is filtered through a short (3 x 5 cm) Florisil column. The column is washed with CH<sub>2</sub>Cl<sub>2</sub> until the washings are colorless, and the combined filtrates are then concentrated in vacuo to a
- 10 volume of 30 mL. Dry hexanes are added until crystallization appears to be complete; approximately 100-125 mL of hexanes are required. The resulting green crystals are collected by filtration, washed with hexane (2 x 15 mL) and dried under dinitrogen to obtain analytically pure ( $\eta^5\text{-C}_5\text{H}_5$ )Mo(NO)<sub>2</sub>Cl (6.0 g, 89 % yield). The chromium and tungsten compounds are obtained similarly (except that the reaction flask is maintained
- 15 at -78°C during the addition of the ClNO) in yields of 77 and 72%, respectively.

Analysis calculated for C<sub>5</sub>H<sub>5</sub>Cr(NO)<sub>2</sub>Cl: C, 28.26; H, 2.37; N, 13.18; Cl, 16.68. Found: C, 28.2; H, 2.55; N, 12.86; Cl, 16.99. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu_{\text{NO}}$  1816, 1711 cm<sup>-1</sup>. EIMS (probe temperature 120°C): *m/z* 212 [P<sup>+</sup>]. mp 144°C (dec).

- Analysis calculated for C<sub>5</sub>H<sub>5</sub>Mo(NO)<sub>2</sub>Cl: C, 23.42; H, 1.96; N, 10.92.
- 20 Found: C, 23.53; H, 1.90; N, 10.70. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu_{\text{NO}}$  1759, 1665 cm<sup>-1</sup>. EIMS (probe temperature 120°C): *m/z* 258 [P<sup>+</sup>]. mp 116°C

Analysis calculated for C<sub>5</sub>H<sub>5</sub>W(NO)<sub>2</sub>Cl: C, 17.44; H, 1.46; N, 8.13; Cl, 10.29. Found: C, 17.68; H, 1.68; N, 8.10; Cl, 10.26. IR (CH<sub>2</sub>Cl<sub>2</sub>):  $\nu_{\text{NO}}$  1733, 1650 cm<sup>-1</sup>. EIMS (probe temperature 120°C): *m/z* 343 [P<sup>+</sup>]. mp 127°C (dec).

25

B. Preparation of Nitrito( $\eta^5$ -cyclopentadienyl)dinitrosylchromium

- CpCr(NO)<sub>2</sub>Cl (1.0 g, 4.7 mmol) (Cp =  $\eta^5\text{-C}_5\text{H}_5$ ) is dissolved in 50 mL distilled water. A distilled water solution (25 mL) of AgNO<sub>2</sub> (0.72 g, 4.7 mmol) is added to the stirred, green solution of CpCr(NO)<sub>2</sub>Cl. A flocculent white solid forms
- 30 immediately. Stirring is continued for 30 min, and then the mixture is filtered to remove the white solid. The filtered solution is extracted with 3 x 50 mL of CH<sub>2</sub>Cl<sub>2</sub>. The extracts are combined, dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The solvent is removed *in vacuo* until the solution reaches a volume of 20 mL. Twenty mL of hexanes are then added, and the mixture is cooled to -30°C to induce crystallization. This
- 35 procedure results in the formation of analytically pure CpCr(NO)<sub>2</sub>(ONO) (0.51 g, 49% yield).

Analysis calculated for  $C_5H_5Cr(NO)_2(ONO)$ : C, 26.92; H, 2.26; N, 18.83. Found: C, 27.21; H, 2.15; N, 18.76. IR ( $CH_2Cl_2$ ):  $\nu_{NO}$  1825, 1719  $cm^{-1}$ .  $^1H$  NMR ( $CDCl_3$ )  $\delta$  5.78 (s). EIMS (probe temperature 120°C):  $m/z$  223 [P<sup>+</sup>].

5

### EXAMPLE 3

#### The Synthesis of Transition-Metal Nitrosyl Complexes with Formula $L_3M(NO)XL$

10 This example presents the syntheses of the transition-metal nitrosyl complexes generally represented by the formula  $L_3M(NO)_yX_{3-y}$  where y is 1 and  $X_2$  is XL:  $L_3M(NO)XL$ .

#### A. Preparation of Iodo( $\eta^5$ -cyclopentadienyl)nitrosylchromium Dimer

15 To a stirred orange solution of  $CpCr(CO)_2(NO)$  (2.03 g, 10.0 mmol) is added solid  $I_2$  (1.24 g, 4.90 mmol). Reaction occurs after 5 min as evidenced by gas evolution and a color change of the reaction mixture to green-brown. After being stirred for 1 h to ensure completion of the reaction, the mixture is taken to dryness under reduced pressure. Crystallization of the residue from  $CH_2Cl_2$ /hexanes affords  
20 dark green  $[CpCr(NO)I]_2$  (2.35 g, 88 % yield)

Analysis calculated for  $[C_5H_5Cr(NO)I]_2$ : C, 21.92; H, 1.84; N, 5.11; I, 46.33. Found: C, 22.00; H, 1.77; N, 5.00; I, 46.08. IR ( $CH_2Cl_2$ ):  $\nu_{NO}$  1673  $cm^{-1}$ . EIMS (probe temperature 120 °C):  $m/z$  548 [P<sup>+</sup>]. mp 119 °C (dec).

#### 25 B. Preparation of Iodo( $\eta^5$ -cyclopentadienyl)nitrosyl(L)chromium (L = $P(OMe)_3$ , pip, py)

Olive green  $[CpCr(NO)I]_2$  (0.27 g, 0.50 mmol) is dissolved in  $CH_2Cl_2$  (20 mL). To the stirred solution, 0.081 mL (1.0 mmol) of pyridine is added by syringe. The color changes from dark green to a brighter green over the period of 30 min. The  
30 solution is reduced in volume to approximately 10 mL, and then filtered through alumina (1.5 x 3 cm) supported on a medium-porosity frit. The column is washed with  $CH_2Cl_2$  until the washings are colorless. Hexanes (30 mL) are added, and the solution is reduced in volume until crystallization is initiated. The mixture is then cooled to -30°C overnight to complete crystallization. The solvent is removed by cannulation, and the  
35 dark green crystals are washed with pentane (3 x 15 mL). This solid is dried in vacuo to obtain 0.32 g (90% yield) of  $CpCr(NO)(py)I$ .

Analysis calculated for  $C_{10}H_{10}N_2OCrI$ : C, 34.02; H, 2.85; N, 7.93. Found: C, 34.15; H, 2.82; N, 7.80. IR (Nujol mull):  $\nu_{NO}$  1651  $cm^{-1}$ . FAB mass spectrum:  $m/z$  353 [P<sup>+</sup>].

The preparation of  $CpCr(NO)(L)I$  where L = piperidine and L = P(OMe)<sub>3</sub> is analogous to above where L = pyridine.

Data for  $CpCr(NO)[P(OMe)_3]I$ : 0.35 g, 88% yield. Analysis calculated for  $C_8H_{14}NO_4PCrI$ : C, 24.13; H, 3.54; N, 3.52. Found: C, 24.19; H, 3.54; N, 3.49. IR (Nujol mull):  $\nu_{NO}$  1650  $cm^{-1}$ . FAB mass spectrum:  $m/z$  398 [P<sup>+</sup>].

Data for  $CpCr(NO)(pip)I$ . Analysis calculated for  $C_{10}H_{16}N_2OCrI$ : C, 33.44; H, 4.49; N, 7.80. Found: C, 33.23; H, 4.46; N, 7.70. IR (Nujol mull):  $\nu_{NO}$  1651  $cm^{-1}$ . FAB mass spectrum:  $m/z$  359 [P<sup>+</sup>]

#### EXAMPLE 4

##### The Synthesis of Transition-Metal Nitrosyl Complexes with Formula $[M(NO)_yX_2]_n$

This example presents the syntheses of transition-metal nitrosyl complexes generally represented by the formula  $[M(NO)_2X_y]_2$  when M is a Group 6 transition metal, y is 2, and when M is a Group 8 transition metal, y is 1.

##### A. Preparation of Dichloro Dinitrosyl Complexes of Molybdenum and Tungsten

A 500-mL, three-necked round-bottom flask is equipped with a gas inlet and an addition funnel, and is charged with powdered  $W(CO)_6$  (17.6 g, 50.0 mmol). The entire system is then thoroughly purged with prepurified dinitrogen and  $CH_2Cl_2$  (90 mL) is added. The addition funnel is charged with a  $CH_2Cl_2$  solution of ClNO (6 mL, 120 mmol). 6 mL of the ClNO solution is added to the flask, and a small amount of air (0.50 mL) is added by syringe to initiate the reaction. The addition of the ClNO solution is carried out in a dropwise manner, the reaction being monitored by IR spectroscopy. When the IR band at 1977  $cm^{-1}$  due to the  $W(CO)_6$  starting material has disappeared, the addition is halted, and the solution is allowed to stir for a further 30 min. The green precipitate which has formed is collected on a glass frit, washed with  $CH_2Cl_2$  and dried in vacuo to obtain  $[W(NO)_2Cl_2]_n$  (14.52 g, 92% yield) as an olive green powder.

Analysis calculated for  $WN_2O_2Cl_2$ : C, 0.00; H, 0.00; N, 8.90; Cl, 22.52. Found: C, 0.23; H, 0.00; N, 8.88; Cl, 21.97. IR (Nujol mull):  $\nu_{NO}$  1794, 1680  $cm^{-1}$ .

The preparation of  $[Mo(NO)_2Cl_2]_n$  is analogous to  $[W(NO)_2Cl_2]_n$  above. Analysis calculated for  $MoN_2O_2Cl_2$ : N, 12.4; Cl, 31.3; Mo, 42.3. Found: N,

12.7; Cl, 32.2; Mo, 41.1. IR (Nujol mull):  $\nu_{\text{NO}}$  1805, 1690  $\text{cm}^{-1}$ . 91% yield based on  $\text{Mo}(\text{CO})_6$ .

B. Preparation of Iodo(dinitrosyl)iron Dimer

5 Dry acetone (250 mL) and 33.5 g (0.3 mol) of iron powder are added to a 1000-mL three-necked round-bottom flask equipped with a gas inlet, a 500-mL pressure-equalizing addition funnel equipped with a bubbler, and a mechanical stirrer. A solution containing 38.1 g (0.1 mol) of  $\text{I}_2$  in  $\text{Et}_2\text{O}$  (300 mL) is then added through the addition funnel dropwise over a period of 45-74 min. After the addition is complete,  
10 NO gas is introduced into the flask at a rate sufficient to maintain a flow of gas of about one bubble per second through the bubbler. Stirring must be sufficiently vigorous to ensure efficient uptake of the NO gas. The end of the reaction is marked by the cessation of the absorption of nitric oxide as determined by the use of the bubbler.

The solvent is removed in vacuo. When the black residue is completely  
15 dry, the desired product is sublimed onto a water-cooled probe. The flask should be heated slowly ( $2^\circ\text{C}/\text{min}$ ) to  $90^\circ\text{C}$ . *Explosive decomposition* can take place if the heating rate is excessive. The product can be scraped off the probe in an inert atmosphere drybox and stored under dinitrogen.

Analysis calculated for  $[\text{Fe}(\text{NO})_2\text{I}]_2$ : Fe, 23.0; I, 52.3. Found: Fe, 23.4; I  
20 51.8. IR (Nujol mull):  $\nu_{\text{NO}}$  1807, 1766  $\text{cm}^{-1}$ .

EXAMPLE 5

Relaxation of Blood Vessels Utilizing Transition-Metal

25 Nitrosyl Complexes

Example 5 presents the results of the evaluation of the efficacy of the transition metal nitrosyl complexes in blood vessel relaxation. In these *in vitro* experiments, phenylephrine pre-constricted rat aortae were subjected to increasing doses  
30 of the transition-metal nitrosyl complexes, and the relaxation of the rat aortae measured. Concentration-response (relaxation) curves were prepared, and the ability of the transition-metal nitrosyl complexes to relax the blood vessels were compared and related to nitroglycerin and sodium nitroprusside. The results of these experiments are reported in terms of  $\text{EC}_{50}$  (effective concentration to produce a 50% relaxation response) and  
35  $\text{E}_{\text{max}}$  (percent relaxation of phenylephrine-induced contraction) and are tabulated in Table 1.

Briefly, rats were sacrificed by a blow on the head followed by exsanguination. The thoracic aorta was removed and cleared of connective tissues. Four ring segments of 0.5 cm length each were prepared from one aorta and suspended in separate organ baths. Each ring was connected to a Grass FT-03-C force-displacement transducer (Quincy, MA) for isometric recording with a pre-load of 1 g and was equilibrated for 1 hr (with 3 washouts) in normal Krebs solution (pH 7.4) at 37°C with a gas mixture of 95 % O<sub>2</sub> and 5 % CO<sub>2</sub>. The Krebs solution had the following composition (10<sup>-3</sup> M): NaCl, 118; glucose, 11; KCl, 4.7; CaCl<sub>2</sub>, 2.5; NaHCO<sub>3</sub>, 25; KH<sub>2</sub>PO<sub>4</sub>, 1.2; MgCl<sub>2</sub>·6H<sub>2</sub>O, 1.2.

Phenylephrine (10<sup>-6</sup> M, EC<sub>90</sub>) was added to the baths and at 15-20 min later, at the steady state phase of the contractile response to phenylephrine, a cumulative concentration-response curve of sodium nitroprusside or a metal nitrosyl complex was constructed using sequential doubling of the drug concentration. Each concentration of a drug was left in the bath for 2-4 min to ensure a plateau response is reached. The time taken to complete each concentration-response curve was approximately 20 min. Figure 1A shows concentration-response curves of CpCr(NO)<sub>2</sub>Cl and CpMo(NO)<sub>2</sub>Cl.

Table 1

The effects of metal nitrosyl complexes on relaxation of pre-constricted aortic rings *in vitro* and depression of mean arterial pressure in conscious rats *in vivo*

5

Entry	Name	<i>In vitro</i>			<i>In vivo</i>		
		n	EC50 ( $\mu$ M)	E <sub>max</sub> (%)	n	ED50 ( $\mu$ g/kg)	E <sub>max</sub> (mmHg) Toxic dose (mg/kg)
1	Na nitroprusside	6	0.052	-128	6	8.4	-58 10,000 <sup>a</sup>
2	Nitroglycerin	6	0.30	-104	6	200	-56 -
3	CpCr(NO) <sub>2</sub> Cl	6	0.11	-118	6	4.4	-42 2,000 <sup>a</sup>
4	CpMo(NO) <sub>2</sub> Cl	6	17	-113	6	400	-59 25,600 <sup>b</sup>
5	CpW(NO) <sub>2</sub> Cl	6	2.0	-122	2	2976	-36 40,000 <sup>c</sup>
6	CpCr(NO)(pip)I	5	0.45	-110	-	-	- -
7	CpW(NO)(CO) <sub>2</sub>	3	2.5	-107	3	-	biphasic <sup>d</sup> 500 <sup>a</sup>
8	[Mo(NO) <sub>2</sub> Cl <sub>2</sub> ] <sub>n</sub>	6	81	-119	2	>5120	no effect -
9	[W(NO) <sub>2</sub> Cl <sub>2</sub> ] <sub>n</sub>	6	335	-108	1	>5120	no effect -
10	[Fe(NO) <sub>2</sub> I] <sub>2</sub>	6	20	-108	2	554	-51 5120 <sup>c</sup>
11	CpCr(NO) <sub>2</sub> (ONO)	6	0.1	-98	2	1.5	-45 1280 <sup>a</sup>

10 <sup>a</sup> denotes dose which caused convulsion

<sup>b</sup> denotes dose which caused death

<sup>c</sup> denotes dose which caused neither convulsion nor death.

<sup>d</sup> denotes depressor followed by pressor response.

EXAMPLE 6Depression of Arterial Blood Pressure Utilizing  
Transition-Metal Nitrosyl Complexes

5

Example 6 describes the results of the determination of the efficacy of the transition-metal nitrosyl complexes in reducing blood pressure of conscious, unrestrained rats. In these *in vivo* experiments, the depression of rat arterial pressure was measured as a function of transition-metal nitrosyl complex dose. Dose-response  
10 (pressure depression) curves were constructed and the capacities of the transition-metal nitrosyl complexes to reduce arterial pressure were compared and related to nitroglycerin and sodium nitroprusside. The results of these experiments are reported in terms of ED<sub>50</sub> (effective dose to produce a 50% pressure depression response) and E<sub>max</sub> (maximum decrease in blood pressure) and are summarized in Example 5, Table 1.

15

The rats were anaesthetized with halothane (4 % in air for induction and 1.5 % in air for surgery). A polyethylene cannula (PE50) was inserted into the left iliac artery for the measurement of mean arterial pressure (MAP) by a pressure transducer (P23DB, Gould Statham, CA). A PE50 cannula was also inserted into the iliac vein for the administration of the vehicle or a drug. The rats were then put into a small cage and  
20 given >6 hr to recover from the effects of anaesthesia and surgery before use. The rats were allowed to move freely during the recovery phase as well as during the conduction of the experiments as described in Wang and Pang, *Br. J. Pharmacol.* 103:2004-8, 1991. Only one dose-response curve of a metal nitrosyl complex, sodium nitroprusside, nitroglycerin or vehicle (0.9% NaCl solution or dimethylsulfoxide solution) was  
25 constructed in each rat. All drugs or vehicle were intravenous bolus injected at dose-intervals of 3-7 min, to allow the recovery of depressor responses, before the injection of the next higher dose.

Five of the eight metal nitrosyl complexes tested were found to lower blood pressure in a dose-related manner. The maximum depressor responses of some of  
30 the metal nitrosyl complexes were similar to those of nitroglycerin and sodium nitroprusside. The potencies (inverse of ED<sub>50</sub>) of some of the metal nitrosyl complexes were similar to or greater than those of nitroglycerin and sodium nitroprusside. Figure 1B shows concentration-response curves of CpCr(NO)<sub>2</sub>Cl and CpMo(NO)<sub>2</sub>Cl.

35

EXAMPLE 7

Example 7 presents the results of pre-exposing the rat aortae to the transition-metal nitrosyl complexes to evaluate the development of tolerance. In these experiments, the rat aortic rings were pretreated with a transition-metal nitrosyl complex prior to the measurement of dose-dependent relaxation as described above in Example 5.

In this study, the vehicles,  $\text{CpCr}(\text{NO})_2\text{Cl}$  ( $10^{-6}$  M), or nitroglycerin ( $3 \times 10^{-4}$  M) was added to the baths for 1 h, followed by the washout of drug or vehicle, precontraction with phenylephrine and the construction of a concentration-relaxation curve of  $\text{CpCr}(\text{NO})_2\text{Cl}$ .

The results show that the pre-incubation with  $\text{CpCr}(\text{NO})_2\text{Cl}$  did not alter the  $\text{EC}_{50}$  or  $\text{E}_{\text{max}}$  of the compound (see Figure 2A), suggesting that tolerance to the tested drug does not readily develop. Pre-incubation with nitroglycerin shifted the nitroglycerin dose-response curve to the right with  $\text{EC}_{50}$  significantly increased and  $\text{E}_{\text{max}}$  unaltered. See Figure 2B. This shows that tolerance develops to nitroglycerin. Pre-exposure to nitroglycerin did not alter the  $\text{EC}_{50}$  or  $\text{E}_{\text{max}}$  of  $\text{CpCr}(\text{NO})_2\text{Cl}$ , showing that no cross-tolerance exists between nitroglycerin and  $\text{CpCr}(\text{NO})_2\text{Cl}$ . See Figure 2C. Pre-exposure to nitroglycerin slightly, but statistically significantly ( $p < 0.05$ ), increased the  $\text{EC}_{50}$  of sodium nitroprusside, suggesting a small degree of cross-tolerance between these two drugs. See Figure 2D.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except by the appended claims.



Claims

1. A method for relaxing smooth muscle in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula



wherein L is a two-electron Lewis base or  $L_3$  is a six-electron Lewis base, M is a Group 6 or 8 transition-metal, and when y is 2, X is either a halide or pseudohalide, and when y is 1,  $X_2$  is either  $L_2$  or XL.

2. The method of claim 1 wherein the smooth muscle is vascular smooth muscle.


3. The method of claim 1 wherein the smooth muscle is nonvascular smooth muscle.

4. A method for treating hypertension in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula



wherein L is a two-electron Lewis base or  $L_3$  is a six-electron Lewis base, M is a Group 6 or 8 transition-metal, and when y is 2, X is either a halide or pseudohalide, and when y is 1,  $X_2$  is either  $L_2$  or XL.

5. A method for treating angina pectoris in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula



wherein L is a two-electron Lewis base or  $L_3$  is a six-electron Lewis base, M is a Group 6 or 8 transition-metal, and when y is 2, X is either a halide or pseudohalide, and when y is 1,  $X_2$  is either  $L_2$  or XL.

6. A method for treating congestive heart failure in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula



wherein L is a two-electron Lewis base or  $L_3$  is a six-electron Lewis base, M is a Group 6 or 8 transition-metal, and when y is 2, X is either a halide or pseudohalide, and when y is 1,  $X_2$  is either  $L_2$  or XL.

7. A method for treating impotence in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula



wherein L is a two-electron Lewis base or  $L_3$  is a six-electron Lewis base, M is a Group 6 or 8 transition-metal, and when y is 2, X is either a halide or pseudohalide, and when y is 1,  $X_2$  is either  $L_2$  or XL, and wherein relaxing smooth muscle is effective in treating impotence.

8. The method according to any one of claim 1, 4, 5, 6 or 7 wherein L is a two-electron Lewis base selected from the group consisting of Group 15 or 16 containing Lewis bases.

9. The method according to any one of claim 1, 4, 5, 6 or 7 wherein L is a two-electron Lewis base selected from the group consisting of pyridine, piperidine, trimethylphosphite, and carbon monoxide.

10. The method according to any one of claim 1, 4, 5, 6 or 7 wherein  $L_3$  is a six-electron Lewis base selected from the group consisting of cyclopentadienyl anion, permethylated cyclopentadienyl anion, and derivatives thereof.

11. The method according to any one of claim 1, 4, 5, 6 or 7 wherein X is a halide is selected from the group consisting of fluoride, chloride, bromide, and iodide.

12. The method according to any one of claim 1, 4, 5, 6 or 7 wherein X is a pseudohalide selected from the group consisting of nitrite, nitrate, and cyanide anion.


13. The method according to any one of claim 1, 4, 5, 6 or 7 wherein the transition-metal nitrosyl complex is selected from the group consisting of chloro( $\eta^5$ -cyclopentadienyl)dinitrosylchromium, chloro( $\eta^5$ -cyclopentadienyl)dinitrosylmolybdenum, and chloro( $\eta^5$ -cyclopentadienyl)dinitrosyltungsten.

14. The method according to any one of claims 1, 4, 5, 6 or 7 wherein the transition-metal nitrosyl complex is nitrito( $\eta^5$ -cyclopentadienyl)dinitrosylchromium.

15. The method according to any one of claims 1, 4, 5, 6 or 7 wherein the transition-metal nitrosyl complex is iodo( $\eta^5$ -cyclopentadienyl)(piperidine)nitrosylchromium.

16. The method according to any one of claim 1, 4, 5, 6 or 7 wherein the transition-metal nitrosyl complex is dicarbonyl( $\eta^5$ -cyclopentadienyl)nitrosyltungsten.

17. A method for relaxing smooth muscle in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula




wherein M is a Group 6 or 8 transition-metal, X is either a halide or pseudohalide, and when M is a Group 6 transition-metal, y is 2, and when M is a Group 8 transition-metal, y is 1.

18. The method of claim 17 wherein the smooth muscle is vascular smooth muscle.


19. The method of claim 17 wherein the smooth muscle is nonvascular smooth muscle.

20. A method for treating hypertension in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula




wherein M is a Group 6 or 8 transition-metal, X is either a halide or pseudohalide, and when M is a Group 6 transition-metal, y is 2, and when M is a Group 8 transition-metal, y is 1.

21. A method for treating angina pectoris in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula




wherein M is a Group 6 or 8 transition-metal, X is either a halide or pseudohalide, and when M is a Group 6 transition-metal, y is 2, and when M is a Group 8 transition-metal, y is 1.

22. A method for treating congestive heart failure in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula



wherein M is a Group 6 or 8 transition-metal, X is either a halide or pseudohalide, and when M is a Group 6 transition-metal, y is 2, and when M is a Group 8 transition-metal, y is 1.

23. A method for treating impotence in a warm-blooded animal, comprising administering to said animal a therapeutically effective amount of a transition-metal nitrosyl complex represented by the formula



wherein M is a Group 6 or 8 transition-metal, X is either a halide or pseudohalide, and when M is a Group 6 transition-metal, y is 2, and when M is a Group 8 transition-metal, y is 1.

24. The method according to any one of claim 17, 20, 21, 22 or 23 wherein X is a halide is selected from the group consisting of fluoride, chloride, bromide, and iodide.

25. The method according to any one of claim 17, 20, 21, 22 or 23 wherein X is a pseudohalide selected from the group consisting of nitrite, nitrate, and cyanide anion.

26. The method according to any one of claim 17, 20, 21, 22 or 23 wherein the transition-metal nitrosyl complex is iodo(dinitrosyl)iron dimer.

27. A pharmaceutical composition, comprising a transition-metal nitrosyl complex represented by the formula



wherein L is a two-electron Lewis base or  $L_3$  is a six-electron Lewis base, M is a Group 6 or 8 transition-metal, and when y is 2, X is either a halide or pseudohalide, and when y is 1,  $X_2$  is either  $L_2$  or XL, and a pharmaceutically acceptable carrier or diluent.

28. The pharmaceutical composition of claim 27 wherein L is a two-electron Lewis base selected from the group consisting of Group 15 or 16 containing Lewis bases.

29. The pharmaceutical composition of claim 27 wherein L is a two-electron Lewis base selected from the group consisting of pyridine, piperidine, trimethylphosphite, and carbon monoxide.

30. The pharmaceutical composition of claim 27 wherein  $L_3$  is a six-electron Lewis base selected from the group consisting of cyclopentadienyl anion, permethylated cyclopentadienyl anion, and derivatives thereof.

31. The pharmaceutical composition of claim 27 wherein X is a halide is selected from the group consisting of fluoride, chloride, bromide, and iodide.

32. The pharmaceutical composition of claim 27 wherein X is a pseudohalide selected from the group consisting of nitrite, nitrate, and cyanide anion.


33. The pharmaceutical composition of claim 27 wherein the transition-metal nitrosyl complex is selected from the group consisting of chloro( $\eta^5$ -cyclopentadienyl)dinitrosylchromium, chloro( $\eta^5$ -cyclopentadienyl)dinitrosyl-molybdenum, and chloro( $\eta^5$ -cyclopentadienyl)dinitrosyltungsten.

34. The pharmaceutical composition of claim 27 wherein the transition-metal nitrosyl complex is nitrito( $\eta^5$ -cyclopenta-dienyl)dinitrosylchromium.

35. The pharmaceutical composition of claim 27 wherein the transition-metal nitrosyl complex is iodo( $\eta^5$ -cyclopenta-dienyl)(piperidine)nitrosylchromium.

36. The pharmaceutical composition of claim 27, 28, 29, 30 or 31 wherein the transition-metal nitrosyl complex is dicarbonyl( $\eta^5$ -cyclopenta-dienyl)nitrosyltungsten.

37. A pharmaceutical composition, comprising a transition-metal nitrosyl complex represented by the formula



wherein M is a Group 6 or 8 transition-metal, X is either a halide or pseudohalide, and when M is a Group 6 transition-metal, y is 2, and when M is a Group 8 transition-metal, y is 1, and a pharmaceutically acceptable carrier or diluent.



38. The pharmaceutical composition of claim 37 wherein X is a halide is selected from the group consisting of fluoride, chloride, bromide, and iodide.

39. The pharmaceutical composition of claim 37 wherein X is a pseudohalide selected from the group consisting of nitrite, nitrate, and cyanide anion.





40. The pharmaceutical composition of claim 37 wherein the transition-metal nitrosyl complex is iodo(dinitrosyl)iron dimer.



1/2

*Fig. 1A**Fig. 1B*

2/2

*Fig. 2A**Fig. 2C**Fig. 2B**Fig. 2D*

# INTERNATIONAL SEARCH REPORT

Inter. Application No

PCT/CA 96/00875

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6    A61K31/28    A61K33/24    A61K33/26		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6    A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 02241 A (UNIV DUKE ;HARVARD COLLEGE (US)) 1 February 1996 * see claims 1-3, 13-15; page 10, 2nd paragraph * ---	1-16, 27-36
A	WO 93 20088 A (US GOVERNMENT) 14 October 1993 * see claim 1, page 5 lines 1-20* ---	1-16, 27-36
A	STRUCT. BONDING, vol. 81, 1993, BERLIN, pages 147-181, XP002039053 CLARKE ET AL.: "Chemistry relevant to the biological effects of nitric oxide and metallonitrosyls" * see in particular pages 176-177 "conclusion" * -----	1-16, 27-36
<div style="display: flex; justify-content: space-between;"> <span><input type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>° Special categories of cited documents :</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>* &amp; * document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center; font-size: 1.2em;">28 August 1997</div>		Date of mailing of the international search report  <div style="text-align: center; font-size: 1.2em;">21. 01. 98</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  <div style="text-align: center; font-size: 1.2em;">INSERT B.</div>

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 96/00875

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1) Claims 1-16,27-36: Pharmaceutical compositions comprising  $L_3M(NO)_yX_{3-y}$  and their use.
- 2) Claims 17-26,37-40: Pharmaceutical compositions comprising  $[M(NO)_2X_y]_2$  and their use.

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-16, 27-36

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 96/00875

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9602241 A	01-02-96	US 5583101 A	10-12-96
		AU 3008395 A	16-02-96
		CA 2194991 A	01-02-96
		US 5545614 A	13-08-96
-----			
WO 9320088 A	14-10-93	US 5389675 A	14-02-95
		AT 155475 T	15-08-97
		AU 3933893 A	08-11-93
		CA 2132847 A	14-10-93
		DE 69312276 D	21-08-97
		DE 69312276 T	02-01-98
		EP 0632812 A	11-01-95
		JP 8501276 T	13-02-96
-----			